Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AbbVie Inc (ABBV) Stock: Skyrocketing On IP Chatter | Coherus Biosciences Inc (CHRS) Stock Tanking

AbbVie Inc (NYSE:ABBV) and Coherus Biosciences Inc (NASDAQ:CHRS) were both off to a relatively normal start in the market today. While both were trading in the green, they weren’t gaining by much. That is, until just after noon, when ABBV started spiking and CHRS began falling apart. Below, we’ll talk about what we’re seeing in the market, why, and what we can expect to see from these stocks ahead.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research


ABBV Climbs While CHRS Takes A Dive

As mentioned above, both AbbVie Inc (NYSE:ABBV) and Coherus Biosciences Inc (NASDAQ:CHRS) were off to a relatively normal start to trading today. While the stocks were both in the green, the movement wasn’t anything to write home about. Nonetheless, that changed minutes after noon with ABBV soaring and CHRS taking a dive. The stocks ended the session at $58.91 per share and $25.60 per share respectively. Those figures represented a 5.12% gain for AbbVie and a 9.06% loss for Coherus.

Why Are These Stocks Moving

As soon as we noticed the movement in the market, the CNA Finance team started to dig to see what was causing the move. It didn’t take long to dig up the cause of the movement in this case. In fact, the movement in both AbbVie and Coherus Biosciences has to do with an IP case.

According to social chatter, ABBV has won their case against CHRS with regard to Humira patent infringement. However, the ruling hasn’t been confirmed by the courts nor by either company.

Follow Abbvie Inc. (NYSE:ABBV)
Trade (NYSE:ABBV) Now!

What We’ll Be Watching Ahead

Moving forward, if this rumor is true, it will prove to be a great thing for ABBV and a horrible thing for Coherus Biosciences Inc (NASDAQ:CHRS). For AbbVie Inc (NYSE:ABBV), the company will prove once again that it is capable of protecting its intellectual property. In the case of Coherus Biosciences, the company will likely take a big hit with regard to the cost of the ruling. Nonetheless, as the story unfolds, we’ll keep you posted!

UPDATE – It has been confirmed that the CHRS patent application has been denied!

Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Trade (NASDAQ:CHRS) Now!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list.

Note: This article was written by Joshua Rodriguez, owner and founder of CNA Finance. If you would like to connect with Joshua, you can do so by emailing him at!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.